Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.

Leuk Lymphoma

b Department of Pathology , Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein, Luebeck , Germany.

Published: October 2016

Download full-text PDF	Source
http://dx.doi.org/10.3109/10428194.2015.1046863	DOI Listing

Publication Analysis

favorable prognostic

prognostic impact

impact ras

ras mutation

mutation status

status multiple

multiple myeloma

myeloma treated

treated high-dose

high-dose melphalan

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!